The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

March 18, 2026 updated by: Yu-kun Luo, Chinese PLA General Hospital

The Clinical Outcomes and Artificial Intelligence Prediction Model of Ultrasound-guided Thermal Ablation for the Treatment of Low-risk Papillary Thyroid Carcinoma

  1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma;
  2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of papillary thyroid carcinoma;

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

3772

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
      • Beijing, China
        • Recruiting
        • Chinese PLA General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patients with low-risk papillary thyroid carcinoma who choose surgery or thermal ablation

Description

Inclusion Criteria:

  1. patients age between 18 and 80 year old, both sex
  2. papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration
  3. the largest diameter ≤2.0 cm
  4. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, nech and chest CT
  5. follow-up period ≥12 months,

Exclusion Criteria:

  1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy
  2. history of neck radiation
  3. history of thyroid surgery
  4. coagulation disorder
  5. serious heart, respiratory, liver, or renal failure
  6. dysfunction of the vocal cord on the opposite side

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
surgery group
patients with low-risk papillary thyroid carcinoma who chose thyroid surgery
Procedure: thyroid surgery
thyroid lobectomy
ablation group
patients with low-risk papillary thyroid carcinoma who chose thermal ablation
Procedure: ultrasound-guided thermal ablation
radiofrequency ablation; microwave ablation or laser ablation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate of disease progression
Time Frame: more than 5 year
cervical lymph node metastases, recurrent tumors and persistent tumors
more than 5 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of complications
Time Frame: 1week
surgery or ablation complications
1week
Rate of tumor disappearance
Time Frame: 2 year
complete disappearance of ablated tumor on ultrasound and contrast-enhanced ultrasound
2 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese PLA General Hospital

Investigators

  • Study Chair: Yukun Luo, Chinese PLA General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2024

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

February 16, 2024

First Submitted That Met QC Criteria

March 16, 2024

First Posted (Actual)

March 19, 2024

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

March 18, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S2023-706

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe